Oakland Southfield Physicians

OSP News

COVID-19 Monoclonal Antibody (mAb) Therapy

Posted: 09/07/2021

Monoclonal antibody (mAb) therapy can be used for both treatment and post-exposure prophylasix for COVID-19. This therapy provides immediate, short-term immunity and has shown to reduce hospitalization and death rates by 70% among high risk COVID-19 patients. It is currently administered by infusion only and an injectable form is under development.

Candidates for mAb include:

  • Treatment
    • COVID19 + and
    • 12 years of age or older (weighs ≥ 40 kg) and
    • Symptomatic for less than 10 days and
    • Has a high-risk medical condition or is 65 years of age or older
  • Post Exposure Prophylaxis
    • Non-vaccinated person with a high-risk medical condition and
    • Close exposure* to someone with COVID-19 
  • Post Exposure Prophylaxis
    • Vaccinated person with a high-risk medical condition and
    • Close exposure* and may not have completed the vaccine series or may not have fully responded to the vaccine

*close exposure is defined by the CDC as within 6 feet of an infected person for 15 minutes or more over a 24-hour period without masking

Treatment is safe and effective for people who have been previously immunized or infected with COVID-19. Patients receiving mAb should receive the COVID vaccine or booster within 90 days of infusion.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.


OSP Technical Support